Jun 24, 2020 08:30AM
Jun 4, 2020 08:00AM
Jul 24, 2019 08:34AM
Jul 24, 2019 08:30AM
Jul 10, 2019 05:30AM
Jun 3, 2019 08:47AM
Jun 3, 2019 08:45AM DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clini
May 20, 2019 05:30AM
May 6, 2019 05:30AM
Apr 4, 2019 05:30AM
Apr 3, 2019 05:40AM
Apr 3, 2019 05:30AM
Feb 20, 2019 05:47AM
Feb 20, 2019 05:30AM DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Nov 20, 2018 05:30AM
Oct 10, 2018 05:30AM
Sep 4, 2018 05:30AM
Jun 26, 2018 06:06AM
Jun 26, 2018 06:00AM
Apr 17, 2018 02:02PM
Apr 17, 2018 02:00PM DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
Apr 16, 2018 09:04AM
Apr 16, 2018 09:00AM
Feb 14, 2018 05:39PM
Dec 26, 2017 08:50AM
Dec 26, 2017 07:26AM
Dec 26, 2017 05:44AM
Dec 26, 2017 05:30AM DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma
Nov 21, 2017 03:08PM
Nov 21, 2017 03:06PM
Nov 13, 2017 06:14PM
Oct 31, 2017 06:38AM
Oct 31, 2017 05:30AM
Oct 3, 2017 05:49AM
Oct 3, 2017 05:30AM DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer
Sep 28, 2017 06:50PM
Sep 27, 2017 05:30AM
Sep 18, 2017 08:15AM
Sep 18, 2017 08:00AM
Sep 11, 2017 06:04AM
Sep 11, 2017 04:00AM
Sep 6, 2017 01:59PM DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
Jul 24, 2017 08:35AM
Jul 24, 2017 08:30AM
Jul 18, 2017 08:31AM
Jul 18, 2017 08:30AM
Jul 11, 2017 08:35AM
Jul 11, 2017 08:30AM
Jun 29, 2017 08:30AM DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable
Jun 22, 2017 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All